Literature DB >> 3961888

Evaluation of a fluorescence polarization immunoassay procedure for quantitation of methotrexate.

M A Pesce, S H Bodourian.   

Abstract

A fluorescence polarization immunoassay (FPIA) procedure for measuring methotrexate was evaluated. The dynamic range of the assay is from 0.05 to 810 microM, and the calibration curve can be stored for at least 2 weeks. The FPIA procedure is automated and rapid; one result can be obtained in 18 min and five results in 25 min. There was no interference from hemoglobin (800 mg/dl), triglycerides (500 mg/dl), bilirubin (20 mg/dl), and protein (12.1 g/dl). Cross-reactivity with 7-hydroxy methotrexate and 2,4-diamino-N-methylpteroic acid was 0.6 and 44%, respectively. The coefficient of variation for the within-run and between-run precision was less than 5.0%. For the comparison studies, the samples were divided into four groups. The methotrexate concentrations in group 1 were 0.05-2.1 microM; in group 2, 2.2-9.3 microM; in group 3, 10-80 microM; and in group 4, greater than 80 microM. Linear regression analysis of the results obtained with the FPIA procedure and the enzyme multiplied immunoassay gave a correlation coefficient of at least 0.95 for all groups.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3961888     DOI: 10.1097/00007691-198603000-00020

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  5 in total

1.  Evaluation of genotoxic risk of handling cytostatic drugs in clinical pharmacy practice.

Authors:  E P Guinée; G H Beuman; G Hageman; I J Welle; J C Kleinjans
Journal:  Pharm Weekbl Sci       Date:  1991-04-26

2.  Biological and environmental monitoring of occupational exposure of pharmaceutical plant workers to methotrexate.

Authors:  P J Sessink; N S Friemèl; R B Anzion; R P Bos
Journal:  Int Arch Occup Environ Health       Date:  1994       Impact factor: 3.015

3.  Intraindividual variability of the bioavailability of low dose methotrexate after oral administration in rheumatoid arthritis.

Authors:  C Lebbe; C Beyeler; N J Gerber; J Reichen
Journal:  Ann Rheum Dis       Date:  1994-07       Impact factor: 19.103

4.  Pharmacokinetic basis for dosing high-dose methotrexate in infants and young children with malignant brain tumours.

Authors:  John C Panetta; Jessica K Roberts; Jie Huang; Tong Lin; Vinay M Daryani; K Elaine Harstead; Yogesh T Patel; Arzu Onar-Thomas; Olivia Campagne; Deborah A Ward; Alberto Broniscer; Giles Robinson; Amar Gajjar; Clinton F Stewart
Journal:  Br J Clin Pharmacol       Date:  2020-01-08       Impact factor: 4.335

5.  Determination of methotrexate in biological fluids and a parenteral injection using terbium-sensitized method.

Authors:  Abolghasem Jouyban; Masoomeh Shaghaghi; Jamshid L Manzoori; Jafar Soleymani; Jalil Jalilvaez-Gharamaleki
Journal:  Iran J Pharm Res       Date:  2011       Impact factor: 1.696

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.